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Zusammenfassung
Hintergrund: Chronische myeloproliferative Erkrankun-
gen (CMPD) scheinen mit einem erhöhten Risiko für pul-
monale Hypertonie (PH) assoziiert zu sein. Kasuistik: Ein
Patient mit chronisch idiopathischer Myelofibrose (CIMF)
wurde aufgrund einer progressiven Belastungsdyspnoe
(New York Heart Association Stadium III) überwiesen. Bis
zu diesem Zeitpunkt erhielt er keine spezifische Behand-
lung seiner CIMF. Echokardiographie und Rechtsherzka-
theter ergaben das Vorliegen einer PH. Eine spezifische
Ursache der PH konnte zunächst ausgeschlossen wer-
den. Somit wurde das Vorliegen einer primären PH ver-
mutet. 2 Jahre später wurde der Patient mit erneut ver-
schlechterter Belastungsdyspnoe vorgestellt, wobei ein
Progress der PH feststellbar war. Einige Tage später ver-
starb der Patient an einem Hinterwandinfarkt. Die Autop-
sie des Lungengewebes zeigte einen Verschluss der klei-
nen Lungengefäße durch Konglomerate von Megakaryo-
zyten. Diskussion: Die Entwicklung der PH ist bei diesem
Patienten als Folge der CMPD einzuschätzen. Das Vorlie-
gen einer PH bei Patienten mit CMPD sollte die Entschei-
dung zu spezifischen therapeutischen Maßnahmen hin-
sichtlich der CMPD beeinflussen.
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Summary
Background: Chronic myeloproliferative disorders
(CMPD) seem to be associated with an increased risk for
pulmonary hypertension (PH). Case Report: A patient
with history of chronic idiopathic myelofibrosis (CIMF)
presented with progressive dyspnea (New York Heart As-
sociation class III). Until this time he had not received
specific treatment for CIMF. Echocardiography and right-
heart catheterization confirmed PH. Further diagnostic
procedures excluded a specific cause of PH. Therefore,
primary PH was assumed. 2 years later he presented
again with progressive dyspnea due to a progress of PH.
A few days later the patient died from acute posterior
myocardial infarction. Pathologic examination of the
lung showed an obstruction of the small vessels by con-
glomerates of megakaryocytes. Discussion: We conclude
that PH developed secondarily due to CMPD. PH should
be suspected in patients with CMPD and should influ-
ence the decision for treatment of CMPD. 
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Introduction
The classification of pulmonary hypertension (PH) according
to the World Health Organization (WHO) 1998 has led to a
descriptive classification of pulmonary hypertension consist-
ing of 5 groups, among them one summarizing miscellaneous
diseases [1]. Several recent case reports and smaller studies
suggest an association of chronic myeloproliferative disorders
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such as polycythemia vera, essential thrombocythemia, or
chronic idiopathic myelofibrosis, and severe pulmonary hyper-
tension [2–6]. In these cases, post-mortem examination of 
the lungs typically reveals intima proliferates and capillary 
occlusion by megakaryocytes as well as extramedullary
hematopoiesis [6]. Likewise, an association of myelodysplastic
syndrome or chronic myeloid leukemia and pulmonary hyper-
tension was reported [5].
Here, we report on a patient who developed severe pul-
monary hypertension due to chronic idiopathic myelofibrosis. 
Case Report
In a 61-year-old male patient chronic idiopathic myelofibrosis (CIMF)
was diagnosed. At this time, he suffered from constitutional weakness and
diffuse pain in muscles and joints. Hepatosplenomegaly was detectable
only by abdominal ultrasound. The peripheral blood showed mild anemia
(7 mmol/l; normal range: 8.6–12.1 mmol/l) and a leukoerythroblastosis
with nucleated red blood cells, granulocyte precursors and tear-drop-
shaped erythrocytes. Fluorescence in-situ hybridisation for the bcr-abl fu-
sion gene was negative. Aspiration of bone marrow was not successful.
Bone marrow biopsy revealed a prefibrotic stage of CIMF with increased
megakaryopoiesis and granulopoiesis with typical abnormalities in matu-
ration of both cell lines. Megakaryocytes showed characteristic ‘cloud-
like’ and ‘balloon-shaped’ nuclei and clustering. Erythropoiesis was de-
creased and iron staining was positive in bone marrow macrophages.
Thus, a diagnosis of other myeloproliferative diseases (e.g. polycythemia
vera or essential thrombocythemia) could be ruled out by histopathologic
and hematologic findings. 
One year after CIMF was diagnosed, the patient was referred to our hos-
pital for the first time due to progressive dyspnea (New York Heart Asso-
ciation class III) and intermittent depending edema. Furthermore, he had
a history of arterial hypertension and atrial fibrillation with consecutive
calcium-channel-blocker and phenprocoumon therapy. The patient had
never smoked in his life. Physical examination revealed a tachypnoeic pa-
tient, hepatosplenomegaly and dependent edema. Analysis of blood gases
showed a mild respiratory partial insufficiency and chest-radiographic
signs of pulmonary hypertension. Echokardiography confirmed a right-
ventricular endsystolic pressure (RVESP) of 65 mmHg and dilatation of
the right ventricle. Subsequently, right-heart catheterization was per-
formed and a cardiac index of 2.6 l/min/m2, a mean pulmonary arterial
pressure of 33 mmHg, a pulmonary vascular resistance of 430 dyn*s*cm-5,
a pulmonary vascular occlusion pressure of 10 mmHg, and a mixed ve-
nous oxygen saturation of 57% was found. The walking distance within 
6 minutes was 320 m.
Bodyplethysmography showed normal ventilatory parameters. Carbon
monoxide diffusion was normal. High-resolution computed tomography
of the chest revealed no significant signs of interstitial lung disease. A ven-
tilation/perfusion scintigraphic scan revealed no signs of pulmonary em-
bolism. Abdominal sonography showed hepatosplenomegaly. Laboratory
investigations revealed mild anemia, no signs of hemolysis, elevation of
creatinine and urea, non-selective proteinuria, slight elevation of rheuma
factors and blood sedimentation. Antinuclear antibodies were normal.
Renal biopsy revealed signs of focal segmental mesangioproliferative
glomerulonephritis of non-IgA type. According to these investigations,
primary pulmonary hypertension was assumed. Therapy with phenpro-
coumon and low-dose calcium antagonists was continued. Bosentan and
prostanoids were not given because these substances were lacking ap-
proval for the therapy of PAH in Germany at this time. Steroid treatment
was started which improved proteinuria but led to steroid-induced dia-
betes mellitus. After discharge from hospital radiation of the spleen was
performed after initiation of a therapy with hydroxurea due to excessive
hepatosplenomegaly.
Two years after the first presentation, the patient was admitted again with
progedient dyspnea, febrile temperature and lumbal pain which had con-
tinued for 3 weeks. His general condition was reduced, signs of cardiac de-
compensation were not found. Laboratory investigation revealed slight
anemia (hemoglobin 7.2 mmol/l), slightly elevated leukocytes (10.5 Gpt/l,
normal range: 3.8–9.8 Gpt/l), C-reactive protein of 180 mg/l (normal: <5
mg/l), and creatinine levels of 165 µmol/l (normal: <115 µmol/l). Lactate
dehydrogenase was increased (47 µmol/s*l, normal range: 2.25–3.75
µmol/s*l). During the course of disease, platelet counts ranged between
500 and 800 Gpt/l (normal range: 150–400 Gpt/l). Cardiac enzymes were
normal and the ECG showed no signs of ischemia. Urine analysis, radio-
graphic and computed tomographic examinations of chest and spine as
well as bone scintigraphic scans showed no foci of infection. Trans-
esophageal echocardiography revealed no signs of endocarditis but a pro-
gressive elevation of the RVESP (85 mmHg) with normal left-ventricular
function. Left atrial blood flow was reduced and a spontaneous echocar-
diographic contrast without formation of thrombotic material was seen.
Sonographically, a progress of hepatosplenomegaly was found. Under
therapy with phenprocoumon, the International Normalized Ratio (INR)
was within therapeutic range. After initiation of antibiotic therapy, the
levels of C-reactive protein decreased. Bone marrow biopsy and right-
heart catheterization were scheduled. 
A few days after admission, the patient collapsed unobserved and was
found dead in the restroom. On autopsy, acute myocardial infarction of
the right coronary artery was found as cause of death. Chronic idiopathic
myelofibrosis with massive hepatosplenomegaly and signs of ex-
tramedullary hematopoesis was confirmed. In the autopsy material an ini-
tial patchy reticulin fibrosis of the bone marrow was detectable; a diffuse
fibrosis, however, was not present; the number of CD34-positive blasts
was not increased. The pulmonary arteries were sclerotic, the right ventri-
cle was hypertrophic and dilated. Examination of the lungs revealed ectat-
ic small vessels with intima proliferates and capillary occlusion by
megakaryocytes (fig. 1). The size and shape of the nuclei of these
megakaryocytes matched the bizarre, ‘cloud-like’ nuclei of the megakary-
ocytes in the bone marrow and extramedullary hematopoesis. 
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Fig. 1. Pulmonary manifestation of chronic idiopathic myelofibrosis
(CIMF) in a patient with PAH: Ectatic and hyperemic precapillary lung
vessels with bizarre-shaped embolizing megakaryocytes (staining against
hematoxylin/ eosine).
Discussion
The groups of pulmonary hypertension (PH) according to the
definition of the WHO in Evian 1998 consist of pulmonary ar-
terial hypertension (PAH), pulmonary venous hypertension,
pulmonary hypertension associated with disorders of the res-
piratory system and/or hypoxemia, pulmonary hypertension
caused by chronic thromboembolic disease, and pulmonary
hypertension associated with miscellaneous diseases [1]. The
group of PAH consists of patients with primary pulmonary hy-
pertension and patients with PAH related to collagenous vas-
cular disease, congenital systemic-pulmonary shunts, portal
hypertension, HIV infection and PAH related to drugs and
toxins. A therapy with prostacyclin, its derivates or with en-
dothelin-receptor antagonists is recommended for these pa-
tients. The Third World Symposium on Pulmonary Arterial
Hypertension in Venice (June 2003), proposed to rank pa-
tients with PAH related to myeloproliferative disorders
among the group of PAH [11]. 
Tumor microembolism leading to PH may be associated with
various tumors [7] and also other systemic diseases such as
amyloidosis may present as PH [8]. In patients with progres-
sive myeloproliferative syndrome, megakaryocyte embolism
of pulmonary vessels may be caused by translocation of
megakaryocytes from the bone marrow, spleen or liver to the
lungs, finally leading to PH [6]. In our patient, PH could be ex-
plained by predominance of ectatic small vessels with intima
proliferates and massive pulmonary capillary occlusion by
megakaryocytes. Unfortunately, the proper diagnosis was only
found post mortem, as also reported previously by Yao et al.
[9]. This case outlines important implications for clinical prac-
tice. Firstly, it demonstrates that PH may be caused directly by
CMPD and should be taken into consideration as a differen-
tial diagnosis when a patient suffers from progressive chronic
dyspnea. Secondly, the rising numbers of reports on pul-
monary hypertension due to various diseases such as hemato-
logic disorders raise the question for an earlier invasive diag-
nostic approach in these patients using transbronchial biopsy
or minimally invasive open lung biopsy. 
Early diagnostic clarification of the etiology of PH is neces-
sary since it might influence the decision for therapy of the
underlying hematologic disorder as well as the early treatment
of PH itself. This is important since it was shown recently that
patients with PH and myelofibrosis might benefit from low-
dose, whole-lung radiotherapy [10].
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